TOP1 is the target of topotecan, which was approved in 1997 by the U.S. Food and Drug Administration (FDA) to treat relapsed ...

The miniature models have the potential to significantly speed up vaccine development, advance cancer treatment research, and enhance health outcomes for a wide range of diseases. To gain deeper ...

A recent study unveiled a key enzyme involved in producing selenoproteins, opening new strategies for treating certain types of cancer in children.

A new drug strategy that regulates the tumor immune microenvironment may transform a tumor that resists immunotherapy into a susceptible one, according to a new study.